Astellas, Medivation team on prostate Rx
Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.
Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
